Clinical trial · Interventional
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
A Phase 3, Randomized-Controlled, Open-Label, Multi-Regional, International Study of Futibatinib (TAS-120) and Zimberelimab (AB122) in Combination With Gemcitabine Plus Cisplatin Versus Durvalumab or Pembrolizumab in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To compare overall survival (OS) of patients in Futibatinib and Zimberelimab in Combination with Gemcitabine plus Cisplatin versus Durvalumab or Pembrolizumab in Combination with Gemcitabine plus Cisplatin for patients with first-line advanced biliary tract cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Biliary Tract Cancer | Malignant Biliary Tract Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cisplatin | Drug | Cisplatin | ALIAS |
| Durvalumab | Drug | Durvalumab | ALIAS |
| Futibatinib | Drug | Futibatinib | ALIAS |
| Gemcitabine | Drug | Gemcitabine | ALIAS |
| Pembrolizumab | Drug | Pembrolizumab | ALIAS |
| Zimberelimab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Treatment Arm
- description
- Futibatinib + Zimberelimab + Gemcitabine + Cisplatin
- interventionNames
- Drug: Futibatinib
- Drug: Zimberelimab
- Drug: Gemcitabine
- Drug: Cisplatin
- type
- ACTIVE_COMPARATOR
- label
- Control Arm
- description
- Investigator's choice; Durvalumab or Pembrolizumab + Gemcitabine + Cisplatin
- interventionNames
- Drug: Durvalumab
- Drug: Pembrolizumab
- Drug: Gemcitabine
- Drug: Cisplatin
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Has histologically confirmed unresectable or advanced biliary tract (i.e. intrahepatic bile duct, extrahepatic bile duct, or gallbladder) cancer that is adenocarcinoma or adenosquamous carcinoma; 2. Has no history of prior treatment for locally advanced or metastatic Biliary Tract Cancer (BTC); * Adjuvant or neoadjuvant chemotherapy is not considered as prior treatment if more than 6 months have passed since its completion. 3. Has radiographically measurable disease per RECIST v1.1. 4. Has a tumor tissue sample available for biomarker analysis in a quantity sufficient. 5. Has an ECOG PS of 0 or 1 before administration of study treatment; Participants with a history of hepatitis B or hepatitis C can be enrolled if they meet study criteria. Exclusion Criteria: 1. History and/or current evidence of clinically significant nontumor-related alteration of calcium-phosphorus homeostasis; 2. History and/or current evidence of clinically significant retinal disorder confirmed by retinal examination; 3. Has prior Fibroblast Growth Factor Receptor (FGFR)-directed therapy including futibatinib 4. Has prior treatment with an anti-Programmed Death Ligand 1 (PD-L1), anti-Programmed Cell Death Protein 1 (PD-1), anti-Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4), anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT), or other immune checkpoint inhibitor (ICI) or agonist as monotherapy or in combination. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
References
Publications (0)
Data not yet available